<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03699839</url>
  </required_header>
  <id_info>
    <org_study_id>2017-01922</org_study_id>
    <nct_id>NCT03699839</nct_id>
  </id_info>
  <brief_title>Reducing the Burden of Influenza After Solid-Organ Transplantation</brief_title>
  <acronym>STOP-FLU</acronym>
  <official_title>Reducing the Burden of Influenza After Solid-Organ Transplantation: the STOP-FLU Trial [Swiss Trial in Solid Organ Transplantation on Prevention of Influenza]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oriol Manuel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Epatocentro Ticino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital Chur</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Influenza is associated with significant morbidity and mortality in solid-organ transplant
      (SOT) recipients and it is mainly prevented by seasonal influenza vaccination. Unfortunately,
      the immunogenicity of standard influenza vaccine is suboptimal in this population.
      Vaccination with a high-dose (HD) influenza vaccine or an MF59-adjuvanted (MF59a) vaccine
      have significantly reduced the incidence of influenza and increased the immunogenicity of
      influenza vaccine in the elderly. The investigators will compare the immunogenicity and
      efficacy of two new vaccination strategies, consisting in vaccination with a HD influenza
      vaccine or an MF59a influenza vaccine, to the standard-dose non-adjuvanted vaccination
      (standard of care) in a population of SOT recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: The primary objective of this study is to compare the immunogenicity of two novel
      vaccination strategies, consisting in vaccination with a HD influenza vaccine or an MF59a
      influenza vaccine, to the standard-dose non-adjuvanted vaccination (standard of care) in a
      population of SOT recipients.

      The main secondary objectives are to evaluate the efficacy of the novel vaccination
      strategies in reducing the incidence of influenza, to correlate the humoral responses to
      vaccination with protection from influenza and to assess the influence of immunosuppression
      on influenza vaccine responses.

      Safety objectives include the assessment of the reactogenicity of the different vaccines and
      to describe the incidence of acute rejection and the development of anti-Human Leucocyte
      Antigens (HLA) antibodies after vaccination.

      Study design: Prospective double-blinded randomized controlled three-arm parallel group
      superiority multicenter trial.

      Inclusion / Exclusion criteria: Study participants will be enrolled among ≥18-year old stable
      SOT recipients ≥3 months after transplantation, regularly followed at their respective
      outpatient clinic at the 7 transplant centers and scheduled to receive the annual influenza
      vaccine. Candidates will be excluded in case of previous severe reaction or allergy to one of
      the study vaccines or in case of treatment for acute rejection, among others.

      Measurements and procedures: At day 0, after giving informed consent, eligible patients will
      be randomized in a 1:1:1 ratio into 3 arms: standard quadrivalent intramuscular vaccine
      (control), HD trivalent vaccine and MF59a trivalent vaccine. After vaccination participants
      will be followed for a period of 6 months. Safety will be assessed immediately after
      vaccination and 7, 28 and 180 days after vaccination, and blood sampling for immunogenicity
      analysis will be performed at baseline, 7, 28 and 180 days after vaccination. Additionally to
      evaluate the vaccine safety, anti-HLA antibodies will be measured at baseline and at days 28
      and 180 after vaccination. Hemagglutinin titers will be determined by hemagglutination
      inhibition assay (HIA) according to standardized methods. During the influenza season, the
      development of influenza will be systematically assessed by polymerase chain reaction (PCR)
      by surveillance nasopharyngeal swab.

      Study Product / Intervention: The study intervention consists in the intramuscular
      administration of either a HD vaccine (containing 60 µg of antigen of each of the three viral
      strains) [Fluzone-HD®] or a MF59a vaccine (containing 15 µg of antigen of each of the three
      viral strains with a MF59 adjuvant) [Fluad®].

      Control Intervention: The control intervention consists in the administration of the standard
      quadrivalent non-adjuvanted intramuscular influenza vaccine (VaxigripTetra®), containing 15
      µg of each of the four viral strains.

      Number of Participants with Rationale: The investigators plan to enroll 780 patients (260
      patients per study group). Sample size was calculated to find a significant difference
      between the three groups for the primary endpoint. The lowest seroconversion rate of 46% for
      standard dose, a mid seroconversion rate of 59% with MF59a vaccine, and the highest
      seroconversion rate of 70% with HD vaccine has been assumed. A 10% drop out rate is assumed
      and the number of patients has been rounded up to get balanced groups. In each group 260
      patients are required which amounts to 780 patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine response rate</measure>
    <time_frame>day 28 after vaccination</time_frame>
    <description>Seroconversion rate for at least one viral antigen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influenza infection</measure>
    <time_frame>Within 6 month after vaccination</time_frame>
    <description>PCR positive for influenza in a nasopharyngeal swab or other clinical specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rates</measure>
    <time_frame>At day 28 and month 6 after vaccination</time_frame>
    <description>Antibody levels &gt;40 after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactogenicity</measure>
    <time_frame>within 28 days after vaccination</time_frame>
    <description>Self-collected adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of anti-HLA antibodies</measure>
    <time_frame>Within 6 months post vaccination</time_frame>
    <description>De novo anti-HLA antibodies measured by Luminex</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">780</enrollment>
  <condition>Influenza</condition>
  <condition>Organ Transplantation</condition>
  <arm_group>
    <arm_group_label>High dose influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of high-dose influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MF59-adjuvanted influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of MF59-adjuvanted vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of standard intramuscular influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-dose influenza vaccine</intervention_name>
    <description>The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.</description>
    <arm_group_label>High dose influenza vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-adjuvanted influenza vaccine</intervention_name>
    <description>The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.</description>
    <arm_group_label>MF59-adjuvanted influenza vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard intramuscular influenza vaccine</intervention_name>
    <description>The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).</description>
    <arm_group_label>Standard influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written, informed consent

          -  Age ≥18 years

          -  Stable outpatients based on clinical judgement

          -  ≥ 3 months after solid organ transplantation

        Exclusion Criteria:

          -  Known hypersensitivity to any component (antigen, adjuvant, excipient or preservative)
             of study vaccines; the composition of the study vaccines is as follows:

               -  VaxigripTetra®: hemagglutinin, egg protein, formaldehyde, octylphenol
                  ethoxylate/octoxynol 9 (Triton® X-100), neomycin

               -  Fluad®: hemagglutinin, neuraminidase, egg protein, squalene, polysorbate 80,
                  sorbitan trioleate, sodium citrate, citric acid, kanamycin sulphate, neomycin
                  sulphate, barium sulphate, formaldehyde, cetyl trimethylammonium bromide

               -  Fluzone-HD®: hemagglutinin, egg protein, formaldehyde, octylphenol
                  ethoxylate/octoxynol 9 (Triton® X-100)

          -  Previous life-threatening reaction to influenza vaccine (i.e. Guillain Barré Syndrome)

          -  Ongoing therapy for rejection (including steroid pulse or prednisone &gt; 2mg/kg/day over
             more than 14 days)

          -  Ongoing therapy with intravenous immunoglobulin (IVIG) and/or eculizumab

          -  Current or past (within 6 months) therapy with rituximab

          -  Abo incompatible transplantation

          -  Unable to comply with study protocol

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oriol Manuel, MD</last_name>
    <phone>+41213143020</phone>
    <email>oriol.manuel@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurélie Mello, MD</last_name>
    <phone>+41213143293</phone>
    <email>aurelie.mello@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospitales Universitarios Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Cordero, MD</last_name>
      <phone>0033955012000</phone>
      <email>mariae.cordero.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital Chur</name>
      <address>
        <city>Chur</city>
        <state>Graubunden</state>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reto Venzin, MD</last_name>
      <phone>+41 81 256 61 11</phone>
      <email>reto.venzin@ksgr.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Dickenmann, MD</last_name>
      <phone>+41 61 265 44 04</phone>
      <email>michael.dickenmann@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uyen Huynh-Do, MD</last_name>
      <phone>+41 31 632 31 44</phone>
      <email>Uyen.Huynh-Do@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Genève</name>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Van Delden, MD</last_name>
      <email>Christian.vanDelden@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Christian Van Delden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oriol Manuel, MD</last_name>
      <phone>+41213143020</phone>
      <email>oriol.manuel@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Matteo Mombelli, MD</last_name>
      <phone>+41795565615</phone>
      <email>matteo.mombelli@chuv.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Epatocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Garzoni, MD</last_name>
      <phone>+41 91 960 85 03</phone>
      <email>christian.garzoni@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canton Hospital St-Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Binet, MD</last_name>
      <phone>+41 71 494 10 32</phone>
      <email>Francoise-Isabelle.Binet@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Mueller, MD</last_name>
      <email>Nicolas.Mueller@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Nicolas Mueller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Kumar D, Michaels MG, Morris MI, Green M, Avery RK, Liu C, Danziger-Isakov L, Stosor V, Estabrook M, Gantt S, Marr KA, Martin S, Silveira FP, Razonable RR, Allen UD, Levi ME, Lyon GM, Bell LE, Huprikar S, Patel G, Gregg KS, Pursell K, Helmersen D, Julian KG, Shiley K, Bono B, Dharnidharka VR, Alavi G, Kalpoe JS, Shoham S, Reid GE, Humar A; American Society of Transplantation H1N1 Collaborative Study Group. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010 Aug;10(8):521-6. doi: 10.1016/S1473-3099(10)70133-X. Epub 2010 Jul 9.</citation>
    <PMID>20620116</PMID>
  </results_reference>
  <results_reference>
    <citation>Manuel O, Estabrook M; AST Infectious Diseases Community of Practice. RNA respiratory viruses in solid organ transplantation. Am J Transplant. 2013 Mar;13 Suppl 4:212-9. doi: 10.1111/ajt.12113.</citation>
    <PMID>23465014</PMID>
  </results_reference>
  <results_reference>
    <citation>Mombelli M, Rettby N, Perreau M, Pascual M, Pantaleo G, Manuel O. Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial. Vaccine. 2018 Oct 1;36(41):6163-6169. doi: 10.1016/j.vaccine.2018.08.057. Epub 2018 Sep 1.</citation>
    <PMID>30181045</PMID>
  </results_reference>
  <results_reference>
    <citation>Kumar D, Campbell P, Hoschler K, Hidalgo L, Al-Dabbagh M, Wilson L, Humar A. Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients. Transplantation. 2016 Mar;100(3):662-9. doi: 10.1097/TP.0000000000000861.</citation>
    <PMID>26335915</PMID>
  </results_reference>
  <results_reference>
    <citation>Koller MT, van Delden C, Müller NJ, Baumann P, Lovis C, Marti HP, Fehr T, Binet I, De Geest S, Bucher HC, Meylan P, Pascual M, Steiger J. Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort. Eur J Epidemiol. 2013 Apr;28(4):347-55. doi: 10.1007/s10654-012-9754-y. Epub 2013 Apr 2.</citation>
    <PMID>23546766</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>Oriol Manuel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Adjuvanted vaccine</keyword>
  <keyword>High-dose vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

